Online inquiry

IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11664MR)

This product GTTS-WQ11664MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets HA gene. The antibody can be applied in Influenza B infection research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_308669.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3654620
UniProt ID Q9Q0U6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ11664MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3152MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA APT070
GTTS-WQ12469MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NN-8226
GTTS-WQ261MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 17-1A
GTTS-WQ14547MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SAR156597
GTTS-WQ3315MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ASN-100
GTTS-WQ6672MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ11736MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MK-0646
GTTS-WQ8458MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HspE7
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW